Siemens Healthineers Annual Shareholders' Meeting 2022

Annual Shareholders’ Meeting 2022: Siemens Healthineers looks back on an outstanding fiscal year and announces further investments

• Siemens Healthineers continues to invest in its employees and expand its locations worldwide
• Production of radiotherapy systems is set to begin later this year in Kemnath, Germany
• Dividend of EUR 0.85 per share proposed for fiscal year 2021

In another year of the pandemic, Siemens Healthineers once again stepped up to take responsibility as one of the world’s most important companies in the healthcare industry. The company and its employees supported medical personnel all over the world along the entire clinical pathway of COVID-19. At the same time, they helped to maintain routine care provided by medical professionals. “The development of Siemens Healthineers in the past fiscal year can only be described as outstanding,” Supervisory Board Chairman Dr. Ralf P. Thomas told this year’s Annual Shareholders’ Meeting of Siemens Healthineers AG. The meeting was again held exclusively online because of the pandemic.

Siemens Healthineers Annual Shareholders’ Meeting approves all agenda items by a large majority

• Shareholders approve dividend of EUR 0.85 per share for fiscal year 2021
• Supervisory Board bids farewell to Managing Board Member Dr. Christoph Zindel

This year’s Annual Shareholders’ Meeting of Siemens Healthineers AG has approved all agenda items by a large majority. At Tuesday’s virtual meeting, shareholders accepted the recommendation of the Managing Board and Supervisory Board to pay a dividend of EUR 0.85 per share for fiscal year 2021. The actions of the Managing and Supervisory Boards in the past fiscal year were ratified by a large majority.

The public speeches of Ralf P. Thomas, Chairman of the Supervisory Board and Bernd Montag, Chairman of the Managing Board can be found here:

Key items of the speeches of the Chairman of the Supervisory Board and of the Chief Executive Officer of Siemens Healthineers AG (Advance publication by February 4, 2022):